Clinical Trial Detail

NCT ID NCT00946647
Title A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

acute myeloid leukemia

myelodysplastic/myeloproliferative neoplasm

Therapies

Panobinostat

Azacitidine

Age Groups: adult

No variant requirements are available.